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Discoidin domain receptor (DDR)1 is a tyrosine kinase-receptor,
which is activated by various types of collagens.1 Several studies
showed DDR1 expression in human cancers, and reported its role
in cell proliferation, epithelial to mesenchymal transition, migra-
tion and invasiveness.2 In addition, high DDR1 expression has
been related to adverse prognosis in some human solid tumours.
As far as haematological malignancies are concerned, DDR1 gene
is highly expressed in adult B-ALL cases without ALL1/AF4 and
E2A/PBX1 molecular rearrangements, as well as in B-cell receptor/
ABL-positive cases.3 Also, acute myeloid leukaemia (AML) blasts
express DDR1, which provides a supportive stimulus in the bone
marrow microenvironment.4 Moreover, activation of DDR1 pro-
tects Hodgkin lymphoma cells from apoptosis. Although Hodgkin
and Reed–Sternberg cells express DDR1, it is not detected in their
normal counterpart, the germinal centre B cells of reactive tonsils.5
The microenvironment of the bone marrow and secondary
lymphoid organs has an essential role in chronic lymphocytic
leukemia (CLL) pathogenesis and resistance to treatment.6 Indeed,
stimuli deriving from the B-cell receptor, cell-to-cell contacts with
nurse-like cells or activated T cells, and several chemokines and
Figure 1. (a–c) High DDR1 gene expression correlates with a shorter time-to-treatment in CLL in three public-access data sets. Cut-off was
median DDR1 value in a and b. In c the best cut-off point for DDR1 gene expression discriminating cases with immunoglobulin variable heavy
(IGVH)mutated from those unmutated was sought by constructing receiver operating character (ROC) analysis. Curves were constructed using
the Kaplan–Meier method and compared with the Wilcoxon log-rank test. (d, e) DDR1 gene expression is higher in CLL with unmutated IGVH
relative to mutated cases (d) and in ZAP70-positive cases relative to negative ones (e) (mean± s.e.m.).
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cytokines promote CLL proliferation and survival.6,7 In a previous
study, we reported that IL-21, which regulates CLL B-cell survival in
a context-dependent fashion, modulates the expression of several
mRNAs, among which DDR1 was one of the most downregulated
genes.8 These data suggested that DDR1 may be expressed in CLL
cells but, to the best of our knowledge, no other studies have
speciﬁcally addressed this issue. Since CLL is a clinically hetero-
geneous disease, here we studied the expression of DDR1 gene in
independent retrospective series of CLL in relationship to time to
ﬁrst treatment (TTFT), known prognostic markers, and miRNA
expression.
To analyse DDR1 mRNA expression we used three public data
sets of CLL gene expression.9–11 The raw gene and miRNA
expression data were retrieved from the NCBI Gene Expression
Omnibus repository (http://www.ncbi.nlm.nih.gov/geo/) through
GEO Series accession numbers GSE22762 (GPL570), GSE39671 and
GSE40571. The raw intensity expression values were processed by
Robust Multi-array Average procedure with the re-annotated Chip
Deﬁnition Files from BrainArray libraries version 18.0.0 available at
http://brainarray.mbni.med.umich.edu. The statistical procedures
were standard functions in base R package (Pearson's product–
moment correlations and Wilcoxon rank-sum tests). TTFT analysis
was performed using the Kaplan–Meier method. A value of
Po0.05 was considered signiﬁcant. To test DDR1 protein
expression, blood samples were obtained with approval of the
Institutional Review Board and informed written consent of the
patients, in accordance with the declaration of Helsinki. Indirect
immunoﬂuorescence with anti-DDR1 murine IgG1 mAb (clone
7A9)12 and Western blot analysis of DDR1 expression were
performed as detailed in the Supplementary information.
Since DDR1 expression correlates with disease progression in
different types of cancers, we ﬁrst analysed DDR1 mRNA in three
public data sets of CLL gene expression. The analysis of these
CLL cohorts, stratiﬁed according to DDR1 cut-off levels, showed
Figure 2. (a) Peripheral blood mononuclear cells from CLL cases express variable levels of surface DDR1 as detected by immunoﬂuorescence
and ﬂuorescence-activated cell sorter analysis, gated on lymphoid cells; (b) western blot analysis of DDR1, ZAP70 and pERK1/2: DDR1 showed
a predominant band of an apparent mw of ~ 130 kDa. K562 erythroleukemia cell line is shown as positive control (c) Densitometry analyses of
ZAP70 and DDR1, relative to actin control, showed a signiﬁcant correlation, whereas no correlation with phosphorylated ERK1/2 (P-ERK) was
found (analysis includes also western blots shown in Supplementary Figure S2).
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that high DDR1 gene expression correlates with a shorter TTFT
(Figures 1a–c). Next, we analysed whether DDR1 expression had
any relationship with known prognostic markers of CLL, such as
ZAP70, CD38 and IGVH mutational status.13 A signiﬁcant, albeit
borderline, correlation between DDR1 and ZAP70 mRNA levels was
found in the GSE22762-GPL570 (r= 0.24, P= 0.0064), GSE39671
(r= 0.31, P= 1.6e-04) and GSE40571 (r= 0.29, P= 4.674e-06) data
sets. Concerning CD38 expression, a weak correlation was found in
the GSE39671 (r= 0.19, P= 0.015) and in the GSE40571 (r= 0.17,
P= 0.0098) data sets. Furthermore, cases with high ZAP70 protein
expression or with unmutated IGVH genes showed higher DDR1
gene expression, in the GSE40571 data set (Figures 1d and e). To
further investigate the DDR1 surface expression and its molecular
form we performed immunoﬂuorescence and western blot
analysis on CLL cells from a small cohort (Supplementary Table
S1). Peripheral blood leukaemia cells express surface DDR1 at
variable levels, in different CLL cases, as detected by immuno-
ﬂuorescence (representative cases are shown in Figure 2a and
Supplementary Figure S1A). Out of 34 CLL tested (Supplementary
Table S2), 11 showed a DDR1 low/negative phenotype (o30% of
DDR1+ cells), 13 were DDR1 bright (465%) and 10 showed
intermediate levels, indicating heterogeneity. Of note, DDR1 is
virtually absent in circulating mature B cells (CD20+) from healthy
donors, whereas DDR1 and CD20 double staining conﬁrmed
expression on leukaemia B cells (Supplementary Figure S1B).
Western blot analysis with an anti-DDR1 antibody showed a
predominant band of ~ 130 kDa, under reducing conditions, which
displayed variable intensity in the different CLL samples (ﬁgure 2B
and Supplementary Figure S2). As control, the K562 erythroleu-
kaemia cell line, known to express full length DDR1,4 showed a
band of the same size. On the basis of the correlation of ZAP70
and DDR1 gene expression, we veriﬁed whether such relationship
also exists at the protein level. To this end, we re-probed the same
blots with an anti-ZAP70 antibody. Densitometry analyses,
normalised to the β-actin content, conﬁrmed the correlation of
ZAP70 and DDR1 at the protein level, in a small independent
cohort (n= 12, r= 0.7413, CI: 0.2733–0.9255, P= 0.0078; Figure 2c).
Since DDR1 expression in activated T cells has been related to
ERK1/2 phosphorylation,14 we also analysed phosphorylated
ERK1/2, but no correlation with DDR1 was found (Figure 2c and
Supplementary Figure S2). Finally, our previous data indicated that
miR663b may downregulate DDR1 expression in response to IL-21
stimulation of CLL cells, in vitro.8 However, we could not ﬁnd a
signiﬁcant anti-correlation between miR663b and DDR1 (data not
shown) by an integrated analysis of gene expression proﬁling and
miRNAome in the proprietary database GSE40571.11 Also,
miR199b-5p, which was reported to downregulate DDR1 expres-
sion in AML,4 showed a good, albeit non-signiﬁcant, reverse
correlation with DDR1 mRNA levels (data not shown).
In this study, we show for the ﬁrst time, that the tyrosine kinase
DDR1 is expressed at the cell surface of circulating B-CLL cells,
although with a remarkable heterogeneity among individual
cases. In addition, DDR1 gene expression correlates with that of
the ZAP70 tyrosine kinase and with the IGVH mutational status,
which are regarded as prognostic markers in CLL.13 Accordingly,
high DDR1 gene expression shows a signiﬁcant relationship with
ZAP70 gene and TTFT in independent CLL cohorts. A similar
correlation between high DDR1 expression and worse prognosis
has been reported in different solid tumours, where DDR1 has
been involved in interaction between stroma and tumour cells.
Indeed, DDR1 acts as a sensor for various types of collagen of the
extracellular matrix, and mediates enhanced tumour cell migra-
tion, survival, proliferation and matrix remodelling.2 Therefore,
DDR1 has a pro-invasive role in different tumours and is studied as
a target for kinase inhibitors. In AML, DDR1 responds to
remodelled type IV collagen present in the stroma of the bone
marrow microenvironment.4 It is conceivable that DDR1 may act
as a sensor for stromal collagen of the bone marrow and lymphoid
tissues also in CLL and provide a supportive stimulus, acting in
concert with other environmental signals. Indeed, DDR1 may act
in concert with other receptor systems. For example, the Insulin-
like growth factor-I (IGF-I)/IGF-I receptor system cooperates with
DDR1 and the G-protein oestrogen receptor to support progres-
sion, in mesothelioma and lung cancer cells.15 In normal T cells,
DDR1 is expressed only upon cell activation through mechanisms,
which involve ERK1/2 signalling. Similarly, normal circulating
B cells or tonsil germinal centre B cells do not express DDR1,5
suggesting that stimuli activating the ERK/1/2 pathway may
induce DDR1 expression in CLL cells. However, the mechanisms
controlling DDR1 expression in CLL remain elusive, since we could
not ﬁnd any correlation between DDR1 expression and constitu-
tive activation of the ERK1/2 pathway. Also, different miRNA have
been reported to regulate DDR1 expression, such as miR199b-5p
in AML cells,4 or IL-21-induced miR663b in B-CLL cells.8 None-
theless, the combined analysis of DDR1 gene and miRNA
expression proﬁles failed to identify signiﬁcant anti-correlations
suggestive of miRNA regulating DDR1 expression, in B-CLL cells. In
conclusion, the correlation of DDR1 mRNA levels with CLL
outcome and other biomarkers of progression suggests a
potential role of DDR1 in CLL biology and lends support to
further studies to address the functional role of DDR1 in this
disease.
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